Jeffrey Graham, MD, University of Manitoba, Winnipeg, Canada, describes some of the most exciting kidney cancer research presented at ASCO GU 2021. The Phase II PAPMET study (NCT02761057) demonstrated that cabozantinib resulted in a significant improvement in progression-free survival in metastatic papillary renal cell carcinoma (pRCC), compared to sunitinib. Dr. Graham also provides an overview of the Phase 3 CLEAR trial (NCT02811861), which evaluated first-line sunitinib monotherapy compared to lenvatinib plus pembrolizumab or everolimus in patients with advanced RCC. This interview took place during the 2021 Genitourinary Cancers Symposium.

свернуть